Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stocks in this Quantisnow insightHealth Care
Historical context for KPTI
Across the 22 sessions after earlier KPTI headlines, the stock closed higher 13 times and lower 9 times, with a median move of 3.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | KPTI | SPY |
|---|---|---|---|
| Jun 4, 2026 | Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 | +0.8% | +0.4% |
| Jun 2, 2026 | Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026and 2 other headlines that session | -6.0% | +0.1% |
| Jun 1, 2026 | Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation | +7.9% | +0.3% |
| May 28, 2026 | Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference | +1.4% | +0.6% |
| May 14, 2026 | Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment | +0.6% | +0.8% |
| May 12, 2026 | Karyopharm to Participate at Upcoming Investor Conferences | +1.2% | -0.2% |
Quantisnow market dataNASDAQ
KPTI
Karyopharm Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2013
Get push alerts for KPTI
Full KPTI profile on Quantisnow Follow KPTI and get a push notification the moment its next story breaks.